Novartis completes divestment of ‘front of eye’ ophthalmology assets
Novartis announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up… read more.
Novartis announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up… read more.
UCLA-led research suggests that diabetes control can significantly improve for Latinos when a pharmacist implements an intervention that addresses these patients’ barriers to medication adherence. In this pharmacist-led… read more.
When PrEP (pre-exposure prophylaxis), a drug that prevents HIV infection, was first approved by the FDA in 2012, it was a medical breakthrough that promised to drastically reduce… read more.
Leqvio (inclisiran), became the first siRNA therapy for dyslipidemia approved in Japan. The drug was approved for familial and non-familial hypercholesterolemia and is intended for patients who are… read more.
Grandmother was right: Scrubbing behind the ears and between the toes may help keep the skin in those regions healthy, or so says a new study by a… read more.
The highest ever number of opioid-related overdose deaths in the United States was recorded in 2020 at 68,630, a 68% increase in just two years. Naloxone is a… read more.
Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for Subcutaneous Injection MA, IN… read more.
Researchers from the Netherlands conducted a qualitative study to explore parental motivations, expectations, and experiences of off-hours primary care contacts for children with acute gastroenteritis. They conducted 14… read more.
Your weekly digest of the top healthcare stories, covering news published from 25/09/2023 – 29/09/2023. Express A staggering £18billion is needed to rescue the beleaguered social care system,… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Litfulo (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe… read more.
A fast-acting medication delivered as a nasal spray may someday allow patients with intermittent rapid heartbeats to treat it themselves as soon as they develop symptoms, according to new research… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.